[{"address1": "1800 El Camino Real", "address2": "Suite D", "city": "Menlo Park", "state": "CA", "zip": "94027", "country": "United States", "phone": "650 331 9090", "website": "https://www.an2therapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.", "fullTimeEmployees": 41, "maxAge": 86400, "priceHint": 4, "previousClose": 2.07, "open": 2.03, "dayLow": 2.01, "dayHigh": 2.14, "regularMarketPreviousClose": 2.07, "regularMarketOpen": 2.03, "regularMarketDayLow": 2.01, "regularMarketDayHigh": 2.14, "beta": -0.146, "forwardPE": -0.88655454, "volume": 94878, "regularMarketVolume": 94878, "averageVolume": 205283, "averageVolume10days": 83220, "averageDailyVolume10Day": 83220, "bid": 2.08, "ask": 2.15, "bidSize": 200, "askSize": 100, "marketCap": 62939188, "fiftyTwoWeekLow": 1.91, "fiftyTwoWeekHigh": 22.22, "fiftyDayAverage": 2.2681, "twoHundredDayAverage": 10.6244, "currency": "USD", "enterpriseValue": -51270724, "floatShares": 14612054, "sharesOutstanding": 29829000, "sharesShort": 693840, "sharesShortPriorMonth": 460513, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0233, "heldPercentInsiders": 0.25169, "heldPercentInstitutions": 0.64131, "shortRatio": 6.45, "shortPercentOfFloat": 0.0361, "impliedSharesOutstanding": 29829000, "bookValue": 3.709, "priceToBook": 0.56888646, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -66026000, "trailingEps": -2.51, "forwardEps": -2.38, "52WeekChange": -0.7284427, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ANTX", "underlyingSymbol": "ANTX", "shortName": "AN2 Therapeutics, Inc.", "longName": "AN2 Therapeutics, Inc.", "firstTradeDateEpochUtc": 1648215000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fa00a21b-8695-3bf1-94dc-fb69ab804327", "messageBoardId": "finmb_645116379", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.11, "targetHighPrice": 25.0, "targetLowPrice": 5.0, "targetMeanPrice": 12.0, "targetMedianPrice": 6.0, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 114210000, "totalCashPerShare": 3.829, "quickRatio": 10.711, "currentRatio": 10.908, "returnOnAssets": -0.4232, "returnOnEquity": -0.6838, "freeCashflow": -34374500, "operatingCashflow": -59285000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]